Mirtazapine Odis Mylan 30 mg orodisp. tabl. Бельгія - голландська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mirtazapine odis mylan 30 mg orodisp. tabl.

viatris gx bv-srl - mirtazapine 30 mg - orodispergeerbare tablet - 30 mg - mirtazapine 30 mg - mirtazapine

Mirtazapine Odis Mylan 15 mg orodisp. tabl. Бельгія - голландська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mirtazapine odis mylan 15 mg orodisp. tabl.

viatris gx bv-srl - mirtazapine 15 mg - orodispergeerbare tablet - 15 mg - mirtazapine 15 mg - mirtazapine

Mirtazapine Odis Mylan 45 mg orodisp. tabl. Бельгія - голландська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mirtazapine odis mylan 45 mg orodisp. tabl.

viatris gx bv-srl - mirtazapine 45 mg - orodispergeerbare tablet - 45 mg - mirtazapine 45 mg - mirtazapine

Azacitidine Celgene Європейський Союз - голландська - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastische middelen - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.